Mount Sinai

Mount Sinai has announced a collaborative research agreement to evaluate a novel liquid radioembolic agent for treating brain tumors. The therapy would deliver radiation directly to tumor tissue in liquid form, an approach being explored for cancers that are difficult to treat surgically. Details on the partner institution, trial design and timeline have not yet been released, and clinical results remain pending.

Researchers at Mount Sinai have developed a wearable AI system that can forecast prolonged sitting in women living with chronic pelvic pain. The technology is aimed at identifying harmful behavior patterns early, potentially allowing patients and clinicians to intervene before symptoms worsen. The announcement highlights growing use of artificial intelligence combined with wearable sensors to manage chronic pain conditions.